BioGend Therapeutics Co., Ltd.
BioGend Therapeutics Co., Ltd. researches, develops, and sells orthopedic medical equipment and related products. It is developing BiG-001 and BiG-006, an osteoinductive bone graft substitute; and BiG-009, an autologous cartilage repair system. The company was incorporated in 2016 and is based in Taipei, Taiwan.
BioGend Therapeutics Co., Ltd. (6733) - Net Assets
Latest net assets as of December 2025: NT$757.64 Million TWD
Based on the latest financial reports, BioGend Therapeutics Co., Ltd. (6733) has net assets worth NT$757.64 Million TWD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$815.38 Million) and total liabilities (NT$57.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$757.64 Million |
| % of Total Assets | 92.92% |
| Annual Growth Rate | -5.34% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 20.33 |
BioGend Therapeutics Co., Ltd. - Net Assets Trend (2021–2025)
This chart illustrates how BioGend Therapeutics Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BioGend Therapeutics Co., Ltd. (2021–2025)
The table below shows the annual net assets of BioGend Therapeutics Co., Ltd. from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$757.64 Million | -10.50% |
| 2024-12-31 | NT$846.51 Million | -11.52% |
| 2023-12-31 | NT$956.77 Million | +30.84% |
| 2022-12-31 | NT$731.27 Million | -22.49% |
| 2021-12-31 | NT$943.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioGend Therapeutics Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12901300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$1.23 Billion | 165.08% |
| Total Equity | NT$742.09 Million | 100.00% |
BioGend Therapeutics Co., Ltd. Competitors by Market Cap
The table below lists competitors of BioGend Therapeutics Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Miciso Real Estate SOCIMI S.A.
MC:YMCS
|
$9.69K |
|
DRAIG RESOURCES
BE:C7H
|
$9.69K |
|
KST BETEILIG N (KSW.SG)
STU:KSW
|
$9.70K |
|
Jr Global Reit
KO:348950
|
$9.70K |
|
Grounded People Apparel Inc.
PINK:GPAIF
|
$9.69K |
|
Robert Walters
LSE:RWA
|
$9.68K |
|
Q2M Managementberatung AG
HM:QBI
|
$9.67K |
|
Visicons Construction and Investment JSC
VN:VC6
|
$9.66K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioGend Therapeutics Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 817,666,000 to 742,093,000, a change of -75,573,000 (-9.2%).
- Net loss of 84,610,000 reduced equity.
- Other factors increased equity by 9,037,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-84.61 Million | -11.4% |
| Other Changes | NT$9.04 Million | +1.22% |
| Total Change | NT$- | -9.24% |
Book Value vs Market Value Analysis
This analysis compares BioGend Therapeutics Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.88x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 4.13x to 5.88x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$8.47 | NT$35.00 | x |
| 2022-12-31 | NT$6.80 | NT$35.00 | x |
| 2023-12-31 | NT$7.62 | NT$35.00 | x |
| 2024-12-31 | NT$6.56 | NT$35.00 | x |
| 2025-12-31 | NT$5.95 | NT$35.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioGend Therapeutics Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -38.05%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.10x
- Recent ROE (-11.40%) is above the historical average (-16.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -15.60% | -1494.07% | 0.01x | 1.15x | NT$-227.24 Million |
| 2022 | -26.24% | -586.58% | 0.04x | 1.17x | NT$-254.74 Million |
| 2023 | -16.61% | -142.23% | 0.10x | 1.12x | NT$-250.42 Million |
| 2024 | -14.24% | -69.47% | 0.18x | 1.12x | NT$-198.24 Million |
| 2025 | -11.40% | -38.05% | 0.27x | 1.10x | NT$-158.82 Million |
Industry Comparison
This section compares BioGend Therapeutics Co., Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioGend Therapeutics Co., Ltd. (6733) | NT$757.64 Million | -15.60% | 0.08x | $9.69K |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |